Timber Pharmaceuticals Inc (NYSE American:TMBR)
| 3.06 Delayed Data As of Sep 22 |  +0.01 / +0.33%Today’s Change | 1.20 Today|||52-Week Range 6.20 | +74.86% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $10.5M |
Company Description
Timber Pharmaceuticals, Inc. engages in the development and commercialization of treatments for orphan dermatologic diseases. Its initial focus is on developing non-systemic treatments for rare dermatologic diseases, including congenital ichthyosis, facial angiofibromas in tuberous sclerosis complex, and other sclerotic skin diseases. The company was founded in 2019 and is headquartered in Warren, NJ.
Contact Information
Timber Pharmaceuticals, Inc. 3 Mountain View Road Warren New Jersey 07059 |
Employees
Shareholders
| Mutual fund holders | 1.88% |
| Other institutional | 1.69% |
| Individual stakeholders | 0.96% |
Top Executives
| John Koconis | Chairman, President & Chief Executive Officer |
| Joe Lucchese | CFO, Secretary, Treasurer & Executive VP |
| Jessica Bruno-Raiz | VP-Clinical Operations & Program Management |
| Alan Mendelsohn | Chief Medical Officer & Executive Vice President |
